Merck & Co. and Moderna maintain a long-standing 50/50 collaboration on their personalized mRNA cancer vaccine intismeran autogene, with Merck leading clinical development and the firms sharing costs and profits equally, rather than pursuing full ownership. Recent positive Phase 3 melanoma data released August 19, 2026, drove sharp share gains but reinforced the partnership model amid Merck’s separate M&A activity in life sciences and oncology diversification ahead of Keytruda patent pressures. With four months remaining in 2026 and no disclosed negotiations or regulatory filings signaling a deal, trader consensus at 98.8% against an announcement reflects the absence of strategic or financial catalysts for consolidation. Tail risks remain limited to an unforeseen competitive threat or major trial setback that could accelerate structural changes.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated1% chance
NEW
NEW
Dec 31, 2026
1% chance
NEW
NEW
Dec 31, 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck & Co. and Moderna maintain a long-standing 50/50 collaboration on their personalized mRNA cancer vaccine intismeran autogene, with Merck leading clinical development and the firms sharing costs and profits equally, rather than pursuing full ownership. Recent positive Phase 3 melanoma data released August 19, 2026, drove sharp share gains but reinforced the partnership model amid Merck’s separate M&A activity in life sciences and oncology diversification ahead of Keytruda patent pressures. With four months remaining in 2026 and no disclosed negotiations or regulatory filings signaling a deal, trader consensus at 98.8% against an announcement reflects the absence of strategic or financial catalysts for consolidation. Tail risks remain limited to an unforeseen competitive threat or major trial setback that could accelerate structural changes.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Market Opened: Aug 19, 2026, 3:58 PM ET
Volume
$425End Date
Dec 31, 2026Market Opened
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck & Co. and Moderna maintain a long-standing 50/50 collaboration on their personalized mRNA cancer vaccine intismeran autogene, with Merck leading clinical development and the firms sharing costs and profits equally, rather than pursuing full ownership. Recent positive Phase 3 melanoma data released August 19, 2026, drove sharp share gains but reinforced the partnership model amid Merck’s separate M&A activity in life sciences and oncology diversification ahead of Keytruda patent pressures. With four months remaining in 2026 and no disclosed negotiations or regulatory filings signaling a deal, trader consensus at 98.8% against an announcement reflects the absence of strategic or financial catalysts for consolidation. Tail risks remain limited to an unforeseen competitive threat or major trial setback that could accelerate structural changes.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Volume
$425End Date
Dec 31, 2026Market Opened
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...Merck & Co. and Moderna maintain a long-standing 50/50 collaboration on their personalized mRNA cancer vaccine intismeran autogene, with Merck leading clinical development and the firms sharing costs and profits equally, rather than pursuing full ownership. Recent positive Phase 3 melanoma data released August 19, 2026, drove sharp share gains but reinforced the partnership model amid Merck’s separate M&A activity in life sciences and oncology diversification ahead of Keytruda patent pressures. With four months remaining in 2026 and no disclosed negotiations or regulatory filings signaling a deal, trader consensus at 98.8% against an announcement reflects the absence of strategic or financial catalysts for consolidation. Tail risks remain limited to an unforeseen competitive threat or major trial setback that could accelerate structural changes.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions